These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 12936973)

  • 1. Pharmacokinetics of linezolid in subjects with renal dysfunction.
    Brier ME; Stalker DJ; Aronoff GR; Batts DH; Ryan KK; O'Grady M; Hopkins NK; Jungbluth GL
    Antimicrob Agents Chemother; 2003 Sep; 47(9):2775-80. PubMed ID: 12936973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-dose linezolid pharmacokinetics in critically ill patients with impaired renal function especially chronic hemodialysis patients.
    El-Assal MI; Helmy SA
    Biopharm Drug Dispos; 2014 Oct; 35(7):405-16. PubMed ID: 25044219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial.
    Stalker DJ; Jungbluth GL
    Clin Pharmacokinet; 2003; 42(13):1129-40. PubMed ID: 14531724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia.
    Nukui Y; Hatakeyama S; Okamoto K; Yamamoto T; Hisaka A; Suzuki H; Yata N; Yotsuyanagi H; Moriya K
    J Antimicrob Chemother; 2013 Sep; 68(9):2128-33. PubMed ID: 23625638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetic analysis of linezolid in low body weight patients with renal dysfunction.
    Tsuji Y; Yukawa E; Hiraki Y; Matsumoto K; Mizoguchi A; Morita K; Kamimura H; Karube Y; To H
    J Clin Pharmacol; 2013 Sep; 53(9):967-73. PubMed ID: 23918457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of linezolid in septic patients with and without extended dialysis.
    Swoboda S; Ober MC; Lichtenstern C; Saleh S; Schwenger V; Sonntag HG; Haefeli WE; Hempel G; Hoppe-Tichy T; Weigand MA
    Eur J Clin Pharmacol; 2010 Mar; 66(3):291-8. PubMed ID: 20013257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure.
    Fiaccadori E; Maggiore U; Rotelli C; Giacosa R; Parenti E; Picetti E; Sagripanti S; Manini P; Andreoli R; Cabassi A
    Crit Care Med; 2004 Dec; 32(12):2437-42. PubMed ID: 15599148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and elimination efficiency of linezolid during dialysis.
    Hiraki Y; Tsuji Y; Misumi N; Hiraike M; Matsumoto K; Morita K; Kamimura H; Karube Y
    Ren Fail; 2013; 35(3):418-20. PubMed ID: 23356475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of repeated dosing of linezolid in a hemodialysis patient with chronic renal failure.
    Tsuji Y; Hiraki Y; Mizoguchi A; Hayashi W; Kamohara R; Kamimura H; Karube Y
    J Infect Chemother; 2008 Apr; 14(2):156-60. PubMed ID: 18622681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects.
    Slatter JG; Stalker DJ; Feenstra KL; Welshman IR; Bruss JB; Sams JP; Johnson MG; Sanders PE; Hauer MJ; Fagerness PE; Stryd RP; Peng GW; Shobe EM
    Drug Metab Dispos; 2001 Aug; 29(8):1136-45. PubMed ID: 11454733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clearance of linezolid via continuous venovenous hemodiafiltration.
    Mauro LS; Peloquin CA; Schmude K; Assaly R; Malhotra D
    Am J Kidney Dis; 2006 Jun; 47(6):e83-6. PubMed ID: 16731287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic evaluation of linezolid in patients with major thermal injuries.
    Lovering AM; Le Floch R; Hovsepian L; Stephanazzi J; Bret P; Birraux G; Vinsonneau C
    J Antimicrob Chemother; 2009 Mar; 63(3):553-9. PubMed ID: 19153078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis.
    Blum RA; Kohli RK; Harrison NJ; Schentag JJ
    Antimicrob Agents Chemother; 1989 Sep; 33(9):1470-6. PubMed ID: 2817847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration.
    Meyer B; Kornek GV; Nikfardjam M; Karth GD; Heinz G; Locker GJ; Jaeger W; Thalhammer F
    J Antimicrob Chemother; 2005 Jul; 56(1):172-9. PubMed ID: 15905303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.
    Flanagan S; Minassian SL; Morris D; Ponnuraj R; Marbury TC; Alcorn HW; Fang E; Prokocimer P
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6471-6. PubMed ID: 25136024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of cidofovir in renal insufficiency and in continuous ambulatory peritoneal dialysis or high-flux hemodialysis.
    Brody SR; Humphreys MH; Gambertoglio JG; Schoenfeld P; Cundy KC; Aweeka FT
    Clin Pharmacol Ther; 1999 Jan; 65(1):21-8. PubMed ID: 9951427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections.
    MacGowan AP
    J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii17-25. PubMed ID: 12730139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients.
    Matsumoto K; Shigemi A; Takeshita A; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y
    Int J Antimicrob Agents; 2014 Sep; 44(3):242-7. PubMed ID: 25108880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment.
    Rubino CM; Bhavnani SM; Loutit JS; Lohse B; Dudley MN; Griffith DC
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis.
    Reitberg DP; Marble DA; Schultz RW; Whall TJ; Schentag JJ
    Antimicrob Agents Chemother; 1988 Apr; 32(4):503-9. PubMed ID: 3377461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.